Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

he requirements and plans for regulatory filings and approvals for clofarabine in additional indications. These risks and uncertainties include, among others, the timing and results of clinical studies for clofarabine; the timing of discussions with the EMEA and FDA regarding clinical study results and approval of clofarabine in additional indications; the timing and content of decisions by the EMEA and FDA related to clinical trials and approval of clofarabine in additional indications; the actual efficacy and safety of clofarabine for the indications in which it is being tested; and the risks and uncertainties described in reports filed by Genzyme with the U.S. Securities and Exchange Commission, including without limitation the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the year ended December 31, 2007. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Genzyme(R) and Evoltra(R) are registered trademarks of Genzyme Corporation or its subsidiaries. All rights reserved.

Media Contact: Investor Contact:

Maria Cantor Patrick Flanigan

(617) 768-6690 (617) 768-6563


'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 21, 2014 Shimadzu Scientific ... LC/MS/MS data tool for the pain management and clinical ... data processing and review by allowing users to highlight ... clinicians. , QuantAnalytics allows analysts to filter results ... expedites data processing by eliminating the need to sift ...
(Date:10/22/2014)... UAE (PRWEB) October 22, 2014 Grace ... science and healthcare projects, announces the addition of ... DCH to its advisory team. Dr. Siddiqui will provide ... , A graduate of University College Medical ... subsequently degreed in medicine in 2001. With further certification ...
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The ... (Medication Dispensing Systems, Packaging and Labeling Systems, Table-top ... Automation) - Global Forecasts & Trends to 2019” ... and opportunities in North America, Europe, Asia-Pacific, and ... 101 market tables and 30 figures spread through ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... QUEBEC CITY, June 3, 2011 Asmacure ... of nicotinic receptor agonists for the treatment of asthma ... has been appointed as chief executive officer.  With a ... the company as it progresses its lead compound, a ...
... /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: CO ... results for the fourth quarter and full year of fiscal ... in the US.   The Company will hold ... 13, 2011 to discuss its financial performance and give a ...
... Pharmaceuticals, Inc. (Nasdaq: ANTH ), today announced ... common stock in an underwritten public offering.  The Company expects ... to an additional 15% of the shares of common stock ...  Citi and Leerink Swann LLC are acting as joint book-running ...
Cached Biology Technology:Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results 2Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
(Date:10/17/2014)... release is available in German . ... of sperms every day in order to reproduce? And why ... the topic of the latest issue of the research journal ... The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has ... is not unusual for a female to copulate with several ...
(Date:10/16/2014)... Mary,s Virginia Institute of Marine Science have received ... Agency to identify the streams and wetlands most ... to help local governments and citizens conserve these ... a dataset of tidal-marsh observations first gathered by ... historical baseline can today,s researchers accurately map the ...
(Date:10/16/2014)... causes severe respiratory tract infections and worldwide claims ... at VIB and Ghent University have succeeded in ... common virus infection. , Xavier Saelens (VIB/UGent): ... the way for the development of a novel ... causes suffering in numerous small children and elderly ...
Breaking Biology News(10 mins):Sperm wars 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3New perspectives for development of an RSV vaccine 2
... In the 1980s, Harald zur Hausen and his co-workers discovered ... Scientists soon found out how these pathogens cause cells to ... viral proteins E6 and E7. Both proteins switch off different ... Dr. Frank Rsl and his co-workers at DKFZ have now ...
... message: Preliminary Press Conference Topics ... of Sciences museum Attention PIOs: Sending Press Releases ... deadline 10 December News Media registration information ... 7 December Who,s coming For important ...
... in warmer water, according to an intriguing new study suggesting ... Experiments with two species of young damselfish on Australia,s Great ... reef fish are either consistently timid, or consistently bold, and ... temperatures rise. A slight lift of just one or ...
Cached Biology News:Papillomavirus silences innate immune response 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6Fish with attitude: Some like it hot 2
... 2800mL wide mouth PYREX Fernbach-style culture flask is ... area to volume ratio. It can also be ... bottom outside edges to achieve maximal oxygen transfer ... 63mm I.D. and accepts cotton plugs or No. ...
... FRT-PGK-gb2-neo-FRT template is designed to ... cells. The FRT-PGK-gb2-neo-FRT template encodes the ... promoter (gb2) for expression of kanamycin resistance ... promoter (PGK) for expression of neomycin resistance ...
These are replacement caps for No. CLS6980 5mm PYREX NMR tubes. Proper method to remove caps is to slice them from the tube. Caps come in eight assorted/mixed colors. Packed in bags of 100....
... inch long PYREX NMR tubes are made from ... valves, and vacuum racks. They are designed for ... 500MHz. They have an O.D. of 4.97 + ... These NMR tubes can be used with the ...
Biology Products: